James Hatton, KC, is a commercial solicitor with experience in assisting companies to exploit the value of their intellectual property assets and fund their development. James is the partner responsible for the Technology Group at FARRIS. He is listed in The Canadian Legal Lexpert Directory, Repeatedly Recommended in Technology Transactions and Life Sciences & Health. Best Lawyers recognizes James in the areas of biotechnology, corporate, intellectual property and technology law. Chambers ranks James nationwide in Life Sciences: Corporate Commercial. Transactions include acting for United Therapeutics in the United Therapeutics Lilly alliance, a US Licensing Executives Society’s Deal of Distinction award winner for the Healthcare Sector. He also acted for the Cardiome Merck alliance, one of the largest cardiovascular life sciences alliances in the world and the largest in the history of the Canadian life sciences industry. James is a former director for BC Hydro, Powerex, BC Tech Association, and The Forum for Women Entrepreneurs. He is an advisory board member for STEMCELL Technologies and past Chair of LifeSciences BC. He is a former member of the National Research Council of Canada and a former member of the board of governors of Royal Roads University.
On August 18, 2015, Diversified Royalty Corp. (DIV) completed an offering of subscription receipts. The offering raised gross proceeds of approximately $115.0 million through the issuance of 42,595,000 subscription receipts, which included 1,854,000 subscription receipts issued as a result of the underwriters electing to exercise the over-allotment option in part. The offering was conducted by a syndicate of underwriters led by Cormark Securities Inc. and including GMP Securities L.P., CIBC World Markets Inc., PI Financial Corp., Beacon Securities Limited and Paradigm Capital Inc.